Provided by Tiger Fintech (Singapore) Pte. Ltd.

IDEAYA Biosciences

21.86
-0.0600-0.27%
Post-market: 21.860.00000.00%16:39 EDT
Volume:1.05M
Turnover:23.06M
Market Cap:1.91B
PE:-6.05
High:22.50
Open:21.87
Low:21.60
Close:21.92
Loading ...

Optimistic Buy Rating for IDEAYA Biosciences: Expanding Market Potential and Promising Clinical Data

TIPRANKS
·
04 Jun

IDEAYA Biosciences Inc. to Participate in Jefferies Global Healthcare Conference 2025

Reuters
·
02 Jun

IDEAYA Biosciences Announces New Inducement Stock Option Plan for Newly Hired Employees

Reuters
·
30 May

IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
30 May

IDEAYA Biosciences Is Maintained at Overweight by JP Morgan

Dow Jones
·
22 May

RBC Capital Reaffirms Their Buy Rating on IDEAYA Biosciences (IDYA)

TIPRANKS
·
08 May

IDEAYA Gets FDA Clearance to Initiate Clinical Trial of Antibody Drug Conjugate Program in Solid Tumors

MT Newswires Live
·
06 May

IDEAYA Biosciences Posts Q1 Net Loss; Cash Runway Extended Through 2029

MT Newswires Live
·
06 May

IDEAYA Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
06 May

BRIEF-IDEAYA Biosciences Announces US FDA IND-Clearance For IDE849, A Potential First-In-Class DLL3 TOP1 ADC, For A Phase 1 Study In Solid Tumors

Reuters
·
06 May

IDEAYA Biosciences Q1 EPS $(0.82) Misses $(0.67) Estimate

Benzinga
·
06 May

Earnings Flash (IDYA) IDEAYA Biosciences Posts Q1 Net Loss $0.82, vs. FactSet Est of $0.66 Loss

MT Newswires Live
·
06 May

IDEAYA Biosciences Reports Q1 2025 Results: Net Loss Down to $72.2M, Increased G&A Expenses Amid Pipeline Support

Reuters
·
06 May

IDEAYA Biosciences Q1 Operating Expenses USD 84.389 Million

THOMSON REUTERS
·
06 May

Press Release: IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

Dow Jones
·
06 May

IDEAYA Biosciences Inc - to Start Phase 1 Study in U.S. Based on FDA Guidance

THOMSON REUTERS
·
06 May

IDEAYA Biosciences Announces US FDA Ind-Clearance for Ide849, a Potential First-in-Class Dll3 Top1 ADC, for a Phase 1 Study in Solid Tumors

THOMSON REUTERS
·
06 May

IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events

PR Newswire
·
28 Apr

BRIEF-Ideaya Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
25 Apr

IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
25 Apr